AAS
RXRX icon

Avantax Advisory Services’s Recursion Pharmaceuticals RXRX Stock Holding History

Avantax Advisory Services’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		$59.8K Buy
+11,815
New +$58K ﹤0.01% 2321

Other funds holding RXRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
KA
Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return
MIC
Mubadala Investment Company Abu Dhabi, United Arab Emirates $34.8B AUM 107.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return

Avantax Advisory Services's RXRX Position: Q2 2025 in Review

Avantax Advisory Services opened a new position in Recursion Pharmaceuticals (RXRX) in Q2 2025: 11,815 shares worth $59.8K. The stake represents ﹤0.01% of the portfolio and ranks #2321 among its holdings.

332 funds tracked by Wall St. Rank hold RXRX as of Q2 2025.

  • Avantax Advisory Services held 11,815 shares of Recursion Pharmaceuticals worth $59.8K as of Q2 2025.
  • Recursion Pharmaceuticals was a new Avantax Advisory Services position in Q2 2025.
  • Recursion Pharmaceuticals made up ﹤0.01% of Avantax Advisory Services's portfolio in Q2 2025, its #2321 holding.
  • 332 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2025.

Based on Avantax Advisory Services's 13F filing for Q2 2025, filed 8 Aug 2025.